Pan-RAS drug shows tumor shrinkage signal in pancreatic cancer as Erasca brings forward plans for a 2027 Phase 3 trial
ERAS-0015 achieved a confirmed objective response rate of 44% in 25 previously treated patients with pancreatic cancer. These early results are driving the company to accelerate development, but more complete evidence is still needed to determine how long the effects last and whether patients receiving first-line treatment can benefit.